In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

Naturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

Updated Part B results demonstrated sustained efficacy for COMP360 psilocybin 25mg, maintaining symptom severity reductions through week 26 after just 1 or 2 doses.

A study of mice fed a high-fat/high-fructose diet (designed to induce obesity) found that 12 weeks of treatment with low-dose psilocybin reduced weight gain, symptoms of fatty liver, hyperglycemia, ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

Also, psilocybin may be headed for approval despite mildly anticlimactic remission rates, and Ocular’s wet AMD drug does .… ...